About Us

There are more than 100 chronic autoimmune diseases - many are severely debilitating, and some life-threatening. The National Institutes of Health estimates that up to 23.5 million Americans suffer from autoimmune disease.

 

At EVOQ Therapeutics, we are intensely focused on delivering innovative immunotherapies to improve the lives of individuals fighting autoimmune disease.

 

Autoimmune disease occurs when the body’s natural immune tolerance system stops working properly. This system failure is responsible for many devastating diseases including – Type 1 Diabetes, Celiac disease, Multiple sclerosis, Rheumatoid Arthritis, Primary Biliary Cholangitis, and Systemic Lupus Erythematosus.

​​

At EVOQ, we’ve designed a breakthrough NanoDisc technology that directly targets the root cause of autoimmune disease and restores the body’s native immune tolerance

 

Unlike other approaches, our proprietary EVOQ NanoDisc delivers the comprehensive targeting necessary to restore the body’s native immune tolerance with simple subcutaneous administration.

 

Following subcutaneous administration, EVOQ NanoDiscs deliver disease-specific antigens directly to dendritic cells in the lymph nodes, liver and spleen. This comprehensive targeting greatly enhances the desired immune response with up to 30 times greater effectiveness versus other methods.

 

Proven in preclinical models for diseases like Type 1 Diabetes, Multiple Sclerosis, and Lupus, our approach offers a promising new path for targeted autoimmune disease therapy with simple administration.